--- title: "Taikang CNI Public Health and Medical Health ETF rose over 1% during trading, showcasing domestic innovative achievements at an international event, and the CXO sector is experiencing a comprehensive recovery" type: "News" locale: "en" url: "https://longbridge.com/en/news/281477633.md" description: "The Taikang CNI Public Health and Medical Health ETF rose over 1% at one point, with a transaction volume of 2.3563 million yuan. The Guotai Guozheng Health Care Sector Index fell by 0.21%. Component stocks showed mixed performance, with Sunshine Guojian Pharmaceutical leading the rise at 12.32%. At the 2026 European Lung Cancer Conference, several domestic pharmaceutical companies showcased cutting-edge technologies and released key clinical data. China International Capital Corporation is optimistic about the CXO sector, expecting double-digit revenue growth in 2026, and suggests seizing the opportunity for industry recovery" datetime: "2026-04-02T06:34:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281477633.md) - [en](https://longbridge.com/en/news/281477633.md) - [zh-HK](https://longbridge.com/zh-HK/news/281477633.md) --- # Taikang CNI Public Health and Medical Health ETF rose over 1% during trading, showcasing domestic innovative achievements at an international event, and the CXO sector is experiencing a comprehensive recovery As of April 2, 2026, 14:03, the Taikang Medical Health ETF (159760) once rose over 1%, with an intraday turnover of 2.76% and a transaction volume of 2.3563 million yuan. The tracked index, Guotai Guozheng Health Care Sector Index (980016), fell by 0.21%. Among the constituent stocks, there were mixed performances: Sunshine Guojian Pharmaceutical led with a rise of 12.32%, Changshan Pharmaceutical increased by 7.62%, and Mindray Medical rose by 3.94%; while Yirui Technology led the decline with a drop of 3.07%, Kanghong Pharmaceutical fell by 2.18%, and Mindray Medical decreased by 1.93%. In terms of news, the 2026 European Lung Cancer Conference (ELCC) was held in Copenhagen from March 25 to 28, where several domestic pharmaceutical companies, including Hengrui Medicine, China National Pharmaceutical Group, CSPC Pharmaceutical Group, Kelun Pharmaceutical, BaiLi Tianheng, Innovent Biologics, Junshi Biosciences, Fuhong Hanlin, and Dize Pharmaceutical, showcased their presence, covering cutting-edge technology paths such as PD-1/VEGF dual antibodies, EGFR/cMET dual antibodies, ADC, dual antibody ADC, KRAS inhibitors, and EGFR-TKI, releasing multiple key clinical data in major disease areas such as non-small cell lung cancer and small cell lung cancer. CICC pointed out that leading CXO companies are gradually disclosing their 2025 annual reports: 1) CDMO companies driven by overseas demand continue to show good operating conditions in terms of orders, performance, and capacity deployment, with a general revenue guidance of double-digit growth for 2026, reflecting management confidence; 2) Clinical CROs and safety assessment CROs oriented towards domestic demand are showing recovery signals of "order volume and price both recovering," transitioning from "order recovery" to "performance realization," with profits expected to gradually reflect in the income statement in 2026 driven by order execution. The institution is firmly optimistic about the current layout opportunities in the CXO sector. The resonance of domestic and overseas demand is expected to drive the industry towards dual recovery in performance and valuation, with leading companies that have technical barriers and platform capabilities being the primary beneficiaries, suggesting to seize the dual opportunities of cyclical recovery and structural upgrading. The Taikang Medical Health ETF closely tracks the Guotai Guozheng Health Care Sector Index, which reflects the market performance of publicly listed companies in the public health and medical health industry in the A-share market. Data shows that as of March 31, 2026, the top ten weighted stocks in the Guotai Guozheng Health Care Sector Index (980016) are WuXi AppTec, Hengrui Medicine, Mindray Medical, New Hope Liuhe, United Imaging Healthcare, Pian Zai Huang, Aier Eye Hospital, Kelun Pharmaceutical, Fosun Pharma, and Rongchang Bio, with the top ten weighted stocks accounting for a total of 50.01%. (The stocks listed above are only constituent stocks of the index and do not imply specific recommendations.) Taikang Medical Health ETF (159760), off-market connection (Taikang Medical Health ETF Initiated Connection A: 020093; Taikang Medical Health ETF Initiated Connection C: 020094) ### Related Stocks - [688336.CN](https://longbridge.com/en/quote/688336.CN.md) - [160219.CN](https://longbridge.com/en/quote/160219.CN.md) - [159760.CN](https://longbridge.com/en/quote/159760.CN.md) - [164401.CN](https://longbridge.com/en/quote/164401.CN.md) ## Related News & Research - [BNB ETF Could Be Next Big Crypto Breakthrough, Says Bloomberg Analyst](https://longbridge.com/en/news/286639724.md) - [VanEck, Grayscale file fresh BNB ETF amendments as race for next altcoin spot ETF accelerates](https://longbridge.com/en/news/286652991.md) - [3 Dividend ETFs to Lock In Before Summer Volatility Picks Up](https://longbridge.com/en/news/286999152.md) - [Worried About a Market Crash? 3 Vanguard ETFs Built to Survive](https://longbridge.com/en/news/286880525.md) - [$100 Invested In iShares S&P 500 Growth ETF 20 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/286800978.md)